ArticleClinical, cosmetic and investigational dermatology2025
Case Report: Pirfenidone-Induced Toxic Epidermal Necrolysisa a Rare Idiosyncratic Reaction.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toxic epidermal necrolysis (TEN) is a rare and low incidence rate disease characterized by pirfenidone-induced skin damage. Pirfenidone is a new anti-fibrotic and anti-inflammatory drug that can alleviate the deterioration of lung function in patients with COVID-19-induced pneumonia and prolong the progression-free survival period. However, side effects of pirfenidone have drawn widespread attention, which include gastrointestinal symptoms, liver damage, skin photosensitivity, and rash. So far, many cases caused by pirfenidone have been reported. As far as we know, cases of TEN induced by pirfenidone have rarely been reported. This article presents cases of TEN induced by pirfenidone, so that clinicians can be aware of the possibility of TEN when using pirfenidone, and how to use inflammation-relevant indicators for evaluating the severity and risk of death of TEN, which has potential clinical value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.